Journey Medical Corp (DERM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Journey Medical Corp stock (DERM) is currently trading at $6.91. Journey Medical Corp PS ratio (Price-to-Sales) is 3.71. Analyst consensus price target for DERM is $13.50. WallStSmart rates DERM as Sell.
- DERM PE ratio analysis and historical PE chart
- DERM PS ratio (Price-to-Sales) history and trend
- DERM intrinsic value — DCF, Graham Number, EPV models
- DERM stock price prediction 2025 2026 2027 2028 2029 2030
- DERM fair value vs current price
- DERM insider transactions and insider buying
- Is DERM undervalued or overvalued?
- Journey Medical Corp financial analysis — revenue, earnings, cash flow
- DERM Piotroski F-Score and Altman Z-Score
- DERM analyst price target and Smart Rating
Journey Medical Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Journey Medical Corp (DERM) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Journey Medical Corp (DERM) Key Strengths (1)
Strong revenue growth at 20.50% annually
Supporting Valuation Data
Journey Medical Corp (DERM) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 8.5x book value
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 3.71x sales
Moderate institutional interest at 41.06%
Journey Medical Corp (DERM) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 20.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.71), Price/Book (8.51) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -47.00%, Operating Margin at -8.67%, Profit Margin at -14.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -47.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 20.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DERM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DERM's Price-to-Sales ratio of 3.71x trades 61% above its historical average of 2.3x (76th percentile), historically expensive. The current valuation is 29% below its historical high of 5.2x set in Nov 2021, and 852% above its historical low of 0.39x in May 2023. Over the past 12 months, the PS ratio has expanded from ~3.0x, reflecting growing market expectations outpacing revenue growth.
Compare DERM with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Journey Medical Corp (DERM) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Journey Medical Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 59M with 21% growth year-over-year. The company is currently unprofitable, posting a -14.6% profit margin.
Key Findings
The company is unprofitable with a -14.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Journey Medical Corp maintain 21%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Journey Medical Corp.
Bottom Line
Journey Medical Corp offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Journey Medical Corp(DERM)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.